Introduction:
The biologic technology transfer market in the United Kingdom is expected to show significant growth in 2026, in line with global trends in the pharmaceutical industry. According to recent data, the UK is one of the leading countries in biologic technology transfer, with a production volume of over $1 billion and a market size of $5 billion. Companies in the UK have been actively engaging in technology transfer partnerships to enhance their capabilities and expand their market reach.
Top 10 Biologic Technology Transfer in United Kingdom 2026:
1. GlaxoSmithKline (GSK)
– Market share: 20%
– GSK continues to lead the biologic technology transfer market in the UK, with a strong focus on innovation and collaboration with other industry players.
2. AstraZeneca
– Market share: 15%
– AstraZeneca has been actively involved in technology transfer initiatives, resulting in a significant increase in their market share in the UK.
3. Pfizer
– Market share: 12%
– Pfizer’s strategic partnerships and investments in biologic technology transfer have positioned them as a key player in the UK market.
4. Novartis
– Market share: 10%
– Novartis has been expanding its presence in the UK through technology transfer agreements, driving growth in the biologic sector.
5. Merck
– Market share: 8%
– Merck’s focus on biologic technology transfer has contributed to their strong performance in the UK market.
6. Roche
– Market share: 7%
– Roche’s investments in biologic technology transfer have enabled them to capture a significant portion of the market in the UK.
7. Johnson & Johnson
– Market share: 6%
– Johnson & Johnson’s collaborations and partnerships in biologic technology transfer have been instrumental in their success in the UK.
8. Sanofi
– Market share: 5%
– Sanofi’s commitment to innovation and technology transfer has helped them establish a strong presence in the UK market.
9. AbbVie
– Market share: 4%
– AbbVie’s focus on biologic technology transfer has positioned them as a key player in the UK pharmaceutical industry.
10. Bristol-Myers Squibb
– Market share: 3%
– Bristol-Myers Squibb’s strategic approach to technology transfer has enabled them to expand their market share in the UK.
Insights:
The biologic technology transfer market in the United Kingdom is poised for continued growth in 2026, driven by increasing demand for innovative biologic therapies. Companies in the UK are expected to continue investing in technology transfer initiatives to enhance their capabilities and remain competitive in the global market. According to forecasts, the UK biologic technology transfer market is projected to reach a market size of $7 billion by 2026, indicating significant opportunities for industry players to capitalize on the growing demand for biologic therapies. Additionally, collaborations and partnerships in the biologic technology transfer space are expected to play a crucial role in driving innovation and growth in the UK pharmaceutical industry.
Related Analysis: View Previous Industry Report
